Gallium-68 DOTATATE (and Cu-64 DOTATATE)
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
Overview
Ga-68 DOTATATE (Netspot, kit) approved June 2016; Cu-64 DOTATATE (Detectnet, 12.7-hour half-life allows central production) approved September 2020; Ga-68 DOTATOC (2019, academic). Changes management in about a third of patients; required before Lu-177 DOTATATE (Lutathera). Also images meningioma and paraganglioma.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
PubChem holds the unlabelled ligand, so the radionuclide itself is not in this drawing.
Radiolabelled somatostatin analogue binding SSTR2 on neuroendocrine tumours; PET replaces the older In-111 octreotide SPECT with higher sensitivity and same-day imaging. Connects to Somatostatin receptor 2.
- PSMA / SSTR-positive cell
1.Gallium-68 DOTATATE (and Cu-64 DOTATATE) slips into a pocket on Somatostatin receptor 2.
- Medicare
- Part B (clinician-administered)
Diagnostic radiopharmaceutical billed with the PET/CT scan under Part B for neuroendocrine tumours (Netspot, Detectnet).
- Commercial insurance
- covered with prior authorisation
Covered for neuroendocrine tumour staging and Lutathera eligibility with prior authorisation of the PET scan.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Diagnostic non-laboratory tests (imaging). Not medical or financial advice; verify with your plan.
- Appraised for
- Somatostatin receptor PET for neuroendocrine tumours
- Notes
- Available at NHS PET centres and required before Lutathera (TA539). No TA.
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE search: gallium-68 DOTATATE PET. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2016 | PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE) |
| US | 2020 | Same (Cu-64 DOTATATE) |
| EU | 2017 | SomaKit TOC (Ga-68 DOTATOC) |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Gallium-68 DOTATATE" OR ABSTRACT:"Gallium-68 DOTATATE" OR TITLE:"and Cu-64 DOTATATE" OR ABSTRACT:"and Cu-64 DOTATATE" OR TITLE:"Netspot" OR ABSTRACT:"Netspot" OR TITLE:"Detectnet" OR ABSTRACT:"Detectnet") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gallium-68 DOTATATE (and Cu-64 DOTATATE), not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentFluciclovine F-18
Shares PET/CT, Gallium-68 and the tag diagnostic.
- AgentFluoroestradiol F-18 (FES PET)
Shares PET/CT and the tag diagnostic.
- PairingSSTR PET → PRRT
Shares 68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE), Theranostic pair, Copper-64, Somatostatin receptor PET (68Ga/64Cu-DOTATATE).
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Theranostics, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- TrialNETTER-1
Shares Krenning score, SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- IndicationNon-small cell lung cancer
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), PET/CT, Gallium-68 and the tag diagnostic.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Curium, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2.
- AgentFlorastamin F-18
Shares Gallium-68, Lutetium-177 and the tag diagnostic.